Nilotinib
- PDF / 130,906 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 20 Downloads / 177 Views
1
S
Bone marrow aplasia: case report A 49-year-old man experienced recurrent bone marrow aplasia while receiving nilotinib. The man started receiving nilotinib 400mg twice per day [route not stated] following a diagnosis of chronic phase chronic myeloid leukaemia. Due to severe cytopenias [time to onset not stated] his dosage was subsequently reduced to 400 mg/day. His dosage of nilotinib was increased back up to 400mg twice daily 6 months later, due to disease progression. Bone marrow aspiration and biopsy 6 months after increasing his dosage showed 5–10% cellularity and a complete cytogenic response. His cytopenias worsened and, 7 months later, bone marrow aspiration and biopsy showed 5% cellularity although he was in complete cytogenic remission. Nilotinib was discontinued. Bone marrow aspiration and biopsy 2 months later showed that the man’s cellularity had improved to 40%. However, his bone marrow showed presence of Ph+ in 13 of 20 metaphases; he started receiving imatinib. Earlier in the course of his disease, prior to starting nilotinib, he had received imatinib but it had been discontinued due to nausea, vomiting and myalgias. Upon restarting imatinib, he developed severe vomiting, nausea and elevated liver enzymes and the drug was discontinued. He subsequently restarted nilotinib 200mg daily; but his cytopenias worsened and his liver enzymes increased. Investigations 1 month later showed 5% cellularity. He discontinued all therapy and his blood counts recovered. Author comment: "Herein, we report a case of a patient who developed severe bone marrow aplasia secondary to nilotinib." Prodduturi P, et al. Recurrent bone marrow aplasia secondary to nilotinib in a patient with chronic myeloid leukemia: A case report. Journal of Oncology Pharmacy Practice 18: 440-444, No. 4, Dec 2012. Available from: URL: http:// 803081832 dx.doi.org/10.1177/1078155212438112 - USA
0114-9954/10/1434-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 12 Jan 2013 No. 1434
Data Loading...
